MAP2K7 and melanoma: Hence, cancer therapy targeting multiple pathways with combinations of SINE, MEK/ERK, PI3K, and kinase inhibitors have been developed for the treatment of melanoma and TC, several of which show improved responses including sorafenib, lenvatinib, and others [47,48,49,50,51,119,120].